TABLE 2.
NSAID | Number of studies |
Acetylsalicylic acid | Rosato et al., 2016; Yang et al., 2016; Belfield et al., 2017; Dotto et al., 2017; Fourie et al., 2017; Xu et al., 2017; Cai et al., 2018; Abidi et al., 2019; Leão et al., 2020; Lin et al., 2020; Santos et al., 2020; Wei et al., 2020 |
Diclofenac | Riordan et al., 2011; Yang et al., 2016; Abbas et al., 2020; Brilhante et al., 2020 |
Ibuprofen | Yang et al., 2016; Shah et al., 2018; Dai et al., 2019; Oliveira et al., 2019 |
Meloxicam | Soheili et al., 2015; She et al., 2018 |
Piroxicam | Soheili et al., 2015; Leão et al., 2020 |
Naproxen | Leão et al., 2020; Yan et al., 2020 |
Sodium salicylate | Belfield et al., 2017; Gerner et al., 2020 |
Celecoxib | Cai et al., 2018; Tzeng et al., 2020 |
Etodolac | Pereira et al., 2018 |
Carprofen | Maitra et al., 2020 |
Mefenamic Acid | Abidi et al., 2019 |